Dr. Leahy received her Ph.D. in Neuropharmacology from University College Dublin, Ireland, and her MBA from Columbia University. She is CEO of PsychoGenics Inc., a profitable preclinical CNS service company CEO of PGI Drug Discovery LLC, a company engaged in psychiatric drug discovery with five partnered clinical programs including one in Phase III. She also holds an Adjunct Associate Professor of Neuroscience position at Mount Sinai School of Medicine. Dr. Leahy has more than 30 years of experience in drug discovery, clinical develop and business development for pharmaceutical and biotechnology companies, Including extensive knowledge of technology assessment, licensing, mergers and acquisitions, and strategic planning. She served on the Emerging Companies Section Governing Board for the Board of Directors of the Biotechnology Industry Organization (BIO), and currently serves on the Board of Directors of Intensity Therapeutics, the Business Review Board for the Alzheimer’s Drug Discovery Foundation, and the Scientific Advisory Board of the International Rett Syndrome Foundation.